PVLA Stock Analysis: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$142.04
-0.54 (-0.38%)
âŧ
5d:
-9.02%
30d:
-0.81%
90d:
+22.53%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PVLA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PVLA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $142.04, which is considered slightly low relative to its 30-day fair value range of $140.15 to $155.42.
Technical Outlook: Technically, PVLA is in a strong uptrend. The price is currently testing key support at $138.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PVLA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $230.53 (+62.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PVLA is in a strong uptrend. The price is currently testing key support at $138.54. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PVLA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $230.53 (+62.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$140.15 -
$155.42
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.3% below Wall St target ($230.53)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$140.15 -
$155.42
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
Âą$11.61
(8.2%)
Support & Resistance Levels
Support Level
$138.54
Resistance Level
$160.33
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.94
Wall Street Target
$230.53
(+62.3%)
Share & Embed Analysis
Last updated: August 23, 2026 8:36 AM ET
Data refreshes hourly during market hours. Next update: 9:36 AM
Data refreshes hourly during market hours. Next update: 9:36 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
1
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Kathleen Goin
SELL
4302 shares
2026-03-18
Elaine J Heron
BUY
2400 shares
2026-02-27
George M Jenkins
BUY
4000 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$834 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
